Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by England, R. W.
Right arrow Articles by Quinn, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by England, R. W.
Right arrow Articles by Quinn, J. M.
(Chest. 2003;123:1014-1017.)
© 2003 American College of Chest Physicians

High-Dose Inhaled Fluticasone and Delayed Hypersensitivity Skin Testing*

Ronald W. England, MD, Capt, USAF, MC; Jeffrey S. Nugent, MD, Capt, USAF, MC; Kurt W. Grathwohl, MD, Maj, USAF, MC; Larry Hagan, MD, Col, USAF, MC and James M. Quinn, MD, Lt Col, USAF, MC

* From Wilford Hall Medical Center, Lackland AFB, San Antonio, TX.

Correspondence to: Ronald W. England, MD, Capt, USAF, MC, 759MDOS/MMIA, 2200 Bergquist Dr., Ste 1, Wilford Hall, TX 78236-5300; e-mail: Ronald.England{at}lackland.af.mil

Introduction: Systemic steroids have been associated with anergy. Treatment with high-dose inhaled steroids has many documented systemic side effects, including adrenal suppression, reduction in growth velocity, and increased bone metabolism; however, little is known about their effect on delayed-type hypersensitivity (DTH).

Study objectives: The purpose of this study was to determine if a 28-day course of high-dose inhaled fluticasone suppresses DTH to a standard panel of antigens.

Methods: Forty-five healthy, steroid-naïve subjects volunteered for this randomized, double-blinded, placebo-controlled trial. All subjects had baseline DTH assessed by intradermal skin testing to a standard panel of antigens (tetanus, candida, mumps, and tuberculin) read 72 h after placement. Subjects were then randomized to receive placebo or high-dose inhaled fluticasone (880 µg/d) for 28 days, after which a second DTH panel was performed. A third DTH panel was performed after a 30-day washout period.

Measurements and results: Of the 45 enrolled subjects, 38 subjects completed the study, including 20 subjects in the placebo group and 18 subjects in the drug group. There was no significant difference in the amount of induration between drug and placebo groups for any of the three periods tested.

Conclusion: Twenty-eight days of treatment with high-dose inhaled fluticasone did not suppress DTH in healthy volunteers.

Key Words: anergy • delayed-type hypersensitivity • inhaled corticosteroids • purified protein derivative testing






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.